Mannose-6-phosphate receptor: A target for theranostics of prostate cancer

59Citations
Citations of this article
70Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The development of personalized and non-invasive cancer therapies based on new targets combined with nanodevices is a major challenge in nanomedicine. In this work, the over-expression of a membrane lectin, the cation-independent mannose 6-phosphate receptor (M6PR), was specifically demonstrated in prostate cancer cell lines and tissues. To efficiently target this lectin a mannose-6-phosphate analogue was synthesized in six steps and grafted onto the surface of functionalized mesoporous silica nanoparticles (MSNs). These MSNs were used for in vitro and ex vivo photodynamic therapy to treat prostate cancer cell lines and primary cell cultures prepared from patient biopsies. The results demonstrated the efficiency of M6PR targeting for prostate cancer theranostic.

Cite

CITATION STYLE

APA

Vaillant, O., Cheikh, K. E., Warther, D., Brevet, D., Maynadier, M., Bouffard, E., … Garcia, M. (2015). Mannose-6-phosphate receptor: A target for theranostics of prostate cancer. Angewandte Chemie - International Edition, 54(20), 5952–5956. https://doi.org/10.1002/anie.201500286

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free